Table 1.
Frequency of lesions in forestomach in WBN/Kob rats treated with a single dose of alloxan
| Weeks after treatment Sex | Alloxan‐treated group | Untreated group | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 40 | 50 (±10) | 70 (±10) | Total | ||||||||
| Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | ||
| Animals | n | 6 | 3 | 14 | 8 | 11 | 6 | 31 | 17 | 24 | 13 |
| Squamous cell hyperplasia | n (%) | 6 (100.0)** | 3 (100.0)**** | 14 (100.0)** | 8 (100.0)**** | 11 (100.0)** | 5 (83.3)**** | 31 (100.0)** | 16 (94.1)**** | 7 (29.2) | 0 (0.0) |
| – | n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (5.9) | 17 (70.8) | 13 (100.0) |
| + | n (%) | 0 (0.0) | 1 (33.3) | 2 (14.3) | 2 (25.0) | 2 (18.2) | 0 (0.0) | 4 (12.9) | 3 (17.6) | 5 (20.8) | 0 (0.0) |
| + + | n (%) | 3 (50.0) | 1 (33.3) | 5 (37.5) | 3 (37.5) | 1 (9.1) | 0 (0.0) | 9 (29.0) | 4 (23.5) | 2 (8.3) | 0 (0.0) |
| + + + | n (%) | 2 (33.3) | 1 (33.3) | 6 (42.9) | 2 (25.0) | 4 (36.4) | 2 (33.3) | 12 (38.7) | 5 (29.4) | 0 (0.0) | 0 (0.0) |
| + + + + | n (%) | 1 (16.7) | 0 (0.0) | 1 (7.1) | 1 (12.5) | 4 (36.4) | 3 (50.0) | 6 (19.4) | 4 (23.5) | 0 (0.0) | 0 (0.0) |
| SCC | n (%) | 1 (16.7) | 0 (0.0) | 2 (14.3) | 1 (12.5) | 3 (27.3)* | 3 (50.0)*** | 6 (19.4)* | 4 (23.5) | 0 (0.0) | 0 (0.0) |
| Adenosquamous carcinoma | n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (9.1) | 0 (0.0) | 1 (3.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Metastasis to lymph node | n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (9.1) | 1 (16.7) | 1 (3.2) | 1 (5.9) | 0 (0.0) | 0 (0.0) |
| Accumulation of neutrophils | n (%) | 6 (100.0)** | 2 (66.7)*** | 13 (92.9)** | 6 (75.0)**** | 8 (72.7)* | 5 (83.3)**** | 27 (87.1)** | 13 (76.5)**** | 7 (29.2) | 0 (0.0) |
| Lymphocyte and plasma cell infiltration in submucosa | n (%) | 6 (100.0)** | 3 (100.0)**** | 14 (100.0)** | 8 (100.0)**** | 11 (100.0)** | 5 (83.3)**** | 31 (100.0)** | 16 (94.1)**** | 6 (25.0) | 0 (0.0) |
| Ulceration or erosion | n (%) | 3 (50.0) | 1 (33.3) | 13 (92.9)** | 5 (62.5)**** | 8 (72.7)** | 5 (83.3)**** | 24 (77.4)** | 11 (64.7)**** | 3 (12.5) | 0 (0.0) |
| Bacterial infection | n (%) | 4 (66.7) | 1 (33.3) | 14 (100.0)** | 8 (100.0)**** | 11 (100.0)** | 5 (83.3)**** | 29 (93.5)** | 14 (82.4)**** | 6 (25.0) | 0 (0.0) |
| Fungal infection | n (%) | 4 (66.7) | 1.(33.3) | 13 (92.9)** | 6 (75.0)**** | 8 (72.7)** | 4 (66.7)**** | 25 (80.6)** | 11 (64.7)**** | 3 (12.5) | 0 (0.0) |
*
P < 0.05,
**
P < 0.01 compared to male rats of untreated group;
***
P < 0.05,
****
P < 0.01 compared to female rats of untreated group. +, slight hyperplasia; + +, moderate hyperplasia; + + +, severe hyperplasia; + + + +, significantly severe hyperplasia.